NXTC · Nextcure, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.83M | - | $6.14M | $24.09M | $7.90M | - | $8.77M | $12.42M | $11.40M | - |
| SG&A | $3.27M | - | $2.81M | $3.20M | $3.73M | - | $3.73M | $4.08M | $4.36M | - |
| Total Operating Expenses | $10.11M | - | $8.95M | $27.29M | $11.62M | - | $12.49M | $16.49M | $18.30M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($10.11M) | - | ($8.95M) | ($27.29M) | ($11.62M) | - | ($12.49M) | ($16.49M) | ($18.30M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($9.80M) | - | ($8.62M) | ($26.81M) | ($10.98M) | - | ($11.54M) | ($15.40M) | ($17.11M) | - |
| EPS - Basic | ($1.87) | - | ($3.22) | ($11.29) | ($0.39) | - | ($0.41) | ($0.55) | ($0.61) | - |
| EPS - Diluted | ($1.87) | - | ($3.22) | ($11.29) | ($0.39) | - | ($0.41) | ($0.55) | ($0.61) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.17M | $25.98M | $7.32M | $4.89M | $21.83M | $27.73M | $27.70M | $20.85M | $18.36M | $13.08M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.07M | $2.01M | $2.39M | $2.54M | $2.74M | $5.35M | $3.61M | $5.08M | $4.49M | $2.33M |
| Current Assets | $31.74M | $43.75M | $32.64M | $40.02M | $58.90M | $71.81M | $78.69M | $90.45M | $102.55M | $112.72M |
| Total Assets | $37.98M | $50.18M | $39.61M | $47.69M | $67.14M | $80.86M | $90.34M | $102.59M | $115.16M | $128.04M |
| Current Liabilities | $6.89M | $10.57M | $10.99M | $10.78M | $5.74M | $9.57M | $8.67M | $10.83M | $9.58M | $6.88M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $11.26M | $15.24M | $15.97M | $16.04M | $11.28M | $15.39M | $14.75M | $17.15M | $16.11M | $13.62M |
| Stockholders' Equity | $26.72M | $34.94M | $23.65M | $29.65M | $55.85M | $65.47M | $75.59M | $85.44M | $99.05M | $114.42M |
| Retained Earnings | ($445.78M) | ($435.98M) | ($426.54M) | ($417.92M) | ($391.11M) | ($380.14M) | ($368.53M) | ($356.99M) | ($341.59M) | ($324.48M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($13.36M) | - | - | - | ($12.99M) | - | - | - | ($12.61M) | - |
| Investing Cash Flow | $1.30M | - | - | - | $7.09M | - | - | - | $17.88M | - |
| Financing Cash Flow | $1.25M | - | - | - | - | - | - | - | $1.0K | - |
| CapEx | - | - | - | - | - | - | - | - | $37.0K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($12.64M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.74 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -25.8% | - | -21.8% | -56.2% | -16.3% | - | -12.8% | -15.0% | -14.9% | - |
| Return on equity | -36.7% | - | -36.5% | -90.4% | -19.7% | - | -15.3% | -18.0% | -17.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.61 | 4.14 | 2.97 | 3.71 | 10.26 | 7.50 | 9.07 | 8.35 | 10.70 | 16.38 |
| Quick ratio | 4.61 | 4.14 | 2.97 | 3.71 | 10.26 | 7.50 | 9.07 | 8.35 | 10.70 | 16.38 |
| Cash ratio | 2.20 | 2.46 | 0.67 | 0.45 | 3.80 | 2.90 | 3.19 | 1.92 | 1.92 | 1.90 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.42 | 1.44 | 1.68 | 1.61 | 1.20 | 1.24 | 1.20 | 1.20 | 1.16 | 1.12 |
| Liabilities / Assets | 0.30 | 0.30 | 0.40 | 0.34 | 0.17 | 0.19 | 0.16 | 0.17 | 0.14 | 0.11 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 13.1% | - | 28.4% | -65.5% | 36.5% | - | 20.0% | 13.9% | -7.2% | - |
| Net income growth (YoY) | 10.8% | - | 25.3% | -74.0% | 35.8% | - | 19.3% | 13.7% | -6.3% | - |
| EPS growth (YoY) | -379.5% | - | -685.4% | -1952.7% | 36.1% | - | 19.6% | 14.1% | -5.2% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 15.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -52.2% | -46.6% | -68.7% | -65.3% | -43.6% | -42.8% | -40.2% | -38.3% | -35.8% | -31.7% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing NextCure against the 5 most active filers in the same SIC group.